75 related articles for article (PubMed ID: 10206297)
1. Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21.
Adluri S; Gilewski T; Zhang S; Ramnath V; Ragupathi G; Livingston P
Br J Cancer; 1999 Apr; 79(11-12):1806-12. PubMed ID: 10206297
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene.
Ding L; Lalani EN; Reddish M; Koganty R; Wong T; Samuel J; Yacyshyn MB; Meikle A; Fung PY; Taylor-Papadimitriou J
Cancer Immunol Immunother; 1993; 36(1):9-17. PubMed ID: 8422670
[TBL] [Abstract][Full Text] [Related]
3. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO
Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527
[TBL] [Abstract][Full Text] [Related]
4. Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn.
Kagan E; Ragupathi G; Yi SS; Reis CA; Gildersleeve J; Kahne D; Clausen H; Danishefsky SJ; Livingston PO
Cancer Immunol Immunother; 2005 May; 54(5):424-30. PubMed ID: 15625606
[TBL] [Abstract][Full Text] [Related]
5. Immunogenic regions of the GA733-2 tumour-associated antigen recognised by autoantibodies of patients with colorectal carcinoma.
Mosolits S; Steinitz M; Harmenberg U; Ruden U; Eriksson E; Mellstedt H; Fagerberg J
Cancer Immunol Immunother; 2002 Jun; 51(4):209-18. PubMed ID: 12012108
[TBL] [Abstract][Full Text] [Related]
6. PankoMab: a potent new generation anti-tumour MUC1 antibody.
Danielczyk A; Stahn R; Faulstich D; Löffler A; Märten A; Karsten U; Goletz S
Cancer Immunol Immunother; 2006 Nov; 55(11):1337-47. PubMed ID: 16485130
[TBL] [Abstract][Full Text] [Related]
7. A genetic variant of immunoglobulin gamma2 is strongly associated with immunity to mucin 1 in patients with breast cancer.
Pandey JP; Nietert PJ; Klaamas K; Kurtenkov O
Cancer Immunol Immunother; 2009 Dec; 58(12):2025-9. PubMed ID: 19365631
[TBL] [Abstract][Full Text] [Related]
8. Lack of evidence for an immunosuppressive role for MUC1.
Paul S; Bizouarne N; Paul A; Price MR; Hansson GC; Kieny MP; Acres RB
Cancer Immunol Immunother; 1999 Apr; 48(1):22-8. PubMed ID: 10235485
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapy.
Pietersz GA; Wenjun L; Krauer K; Baker T; Wreschner D; McKenzie IF
Cancer Immunol Immunother; 1997 Aug; 44(6):323-8. PubMed ID: 9298934
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, conformational analysis and
Bermejo IA; Navo CD; Castro-López J; Guerreiro A; Jiménez-Moreno E; Sánchez Fernández EM; García-Martín F; Hinou H; Nishimura SI; García Fernández JM; Mellet CO; Avenoza A; Busto JH; Bernardes GJL; Hurtado-Guerrero R; Peregrina JM; Corzana F
Chem Sci; 2020 Mar; 11(15):3996-4006. PubMed ID: 34122869
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and immunological evaluation of synthetic peptide based anti-SARS-CoV-2 vaccine candidates.
Zhao Q; Gao Y; Xiao M; Huang X; Wu X
Chem Commun (Camb); 2021 Feb; 57(12):1474-1477. PubMed ID: 33443248
[TBL] [Abstract][Full Text] [Related]
12. Synthetic MUC1 breast cancer vaccine containing a Toll-like receptor 7 agonist exerts antitumor effects.
Liu Y; Tang L; Gao N; Diao Y; Zhong J; Deng Y; Wang Z; Jin G; Wang X
Oncol Lett; 2020 Sep; 20(3):2369-2377. PubMed ID: 32782554
[TBL] [Abstract][Full Text] [Related]
13. Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice.
Wu X; Yin Z; McKay C; Pett C; Yu J; Schorlemer M; Gohl T; Sungsuwan S; Ramadan S; Baniel C; Allmon A; Das R; Westerlind U; Finn MG; Huang X
J Am Chem Soc; 2018 Dec; 140(48):16596-16609. PubMed ID: 30398345
[TBL] [Abstract][Full Text] [Related]
14. Antitumor Humoral and T Cell Responses by Mucin-1 Conjugates of Bacteriophage Qβ in Wild-type Mice.
Yin Z; Wu X; Kaczanowska K; Sungsuwan S; Comellas Aragones M; Pett C; Yu J; Baniel C; Westerlind U; Finn MG; Huang X
ACS Chem Biol; 2018 Jun; 13(6):1668-1676. PubMed ID: 29782143
[TBL] [Abstract][Full Text] [Related]
15. Synthetic self-adjuvanting glycopeptide cancer vaccines.
McDonald DM; Byrne SN; Payne RJ
Front Chem; 2015; 3():60. PubMed ID: 26557640
[TBL] [Abstract][Full Text] [Related]
16. Natural and adaptive IgM antibodies in the recognition of tumor-associated antigens of breast cancer (Review).
Díaz-Zaragoza M; Hernández-Ávila R; Viedma-Rodríguez R; Arenas-Aranda D; Ostoa-Saloma P
Oncol Rep; 2015 Sep; 34(3):1106-14. PubMed ID: 26133558
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the development of breast cancer vaccines.
Milani A; Sangiolo D; Aglietta M; Valabrega G
Breast Cancer (Dove Med Press); 2014; 6():159-68. PubMed ID: 25339848
[TBL] [Abstract][Full Text] [Related]
18. Natural and Induced Humoral Responses to MUC1.
Von Mensdorff-Pouilly S; Moreno M; Verheijen RH
Cancers (Basel); 2011 Jul; 3(3):3073-103. PubMed ID: 24212946
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.
Emens LA
Expert Rev Anticancer Ther; 2012 Dec; 12(12):1597-611. PubMed ID: 23253225
[TBL] [Abstract][Full Text] [Related]
20. Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.
Madsen CB; Petersen C; Lavrsen K; Harndahl M; Buus S; Clausen H; Pedersen AE; Wandall HH
PLoS One; 2012; 7(11):e50139. PubMed ID: 23189185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
